The Food and Drug Administration maintained a neutral stance on COVID-19 booster shots in advance of a Friday vote. FDA reviewers pointed out that people who are fully vaccinated are still protected from severe illness and death, though Pfizer has argued efficacy increases with boosters. (The Washington Post)

Moderna announced Wednesday that immunity from its COVID-19 vaccine declines over time. The company’s announcement added to the growing debate over whether fully vaccinated people benefit from booster shots. (Reuters)

The FDA has reversed a previous decision and will review an experimental amyotrophic lateral sclerosis (ALS) treatment from Amylyx Pharmaceuticals. The reversal is seen as a victory for ALS patients and advocates. (STAT)

Moderna will partner with AbCellera to develop new mRNA therapies. Moderna plans to use AbCellera’s antibody discovery platform to produce mRNA-encoded drugs. (Endpoints News)

Moderate Democrats voted against their party’s drug pricing measure in a House committee Wednesday. The opposition is a setback for the Democrats’ attempt to add drug pricing reform into their $3.5 trillion bill, though it’s likely some form of regulation around pricing will make it into the final version. (The Hill)